title: Therapeutic perspectives in atopic dermatitis.
abstract: Therapy of atopic dermatitis should comprise emollients, topical glucocorticosteroids, or calcineurin inhibitors, phototherapies, immunosuppressants like cyclosporin A, and other treatments. All these treatments should be improved, thanks to research. But new therapeutic perspectives should be given by topical anti-inflammatory substances, selective glucocorticoid receptor agonists, probiotics, interferon γ, TNFα inhibitors, inhibition of T cells or B cells, inhibition of IgE binding, and many other possibilities.
authors.affiliation: Department of Dermatology, Laboratory of Skin Neurobiology, University Hospital, University of Brest, France. laurent.misery@chu-brest.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Misery
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D003876:Dermatitis, Atopic / Q000628:therapy*; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000187:drug effects; D008212:Lymphocyte Depletion; D011485:Protein Binding / Q000187:drug effects; D011965:Receptors, Glucocorticoid / Q000819:agonists; D013601:T-Lymphocytes / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D011965:Receptors, Glucocorticoid; D014409:Tumor Necrosis Factor-alpha; D007073:Immunoglobulin E; D007371:Interferon-gamma